We help clinicians and health systems deliver timely, safe, evidence-based treatment for treatment-resistant schizophrenia (TRS)—through consultation, education, and hands-on implementation support, so people get the right care from their own providers.
Clozapine is the only FDA-approved medication for treatment-resistant schizophrenia (TRS), yet it is significantly underused. In the post-REMS era, with simplified monitoring requirements and updated clinical guidelines, there are fewer barriers to clozapine access than ever before.
TRS ACCESS—Advocacy, Clinical Consultation, Education, and Support Service—is building a network of clinicians and clinics ready to deliver timely, evidence-based TRS care. We help health systems and providers expand safe, effective use of clozapine and long-acting injectable antipsychotics, improving outcomes for people with TRS.
The TRS ACCESS Network is supported by the generous philanthropy of the CNR Foundation.
Abigail Donovan, MD explains our mission
Learn about the comprehensive approach behind TRS ACCESS and how we're helping clinicians become capable of prescribing clozapine and long-acting injectables safely and effectively for people with treatment-resistant schizophrenia.
A lighthouse is a beacon of hope in a sea of uncertainty.
Clozapine is proven to be the most effective treatment for TRS, but many people never receive it. The TRS ACCESS Network exists to close this gap by supporting earlier, safer, and more consistent use of clozapine and other best-practice interventions.
We partner with clinicians, clinics, and health systems to:
Abigail Donovan, MD explains the importance improving health outcomes
Understanding the critical importance of measuring and improving outcomes for people with treatment-resistant schizophrenia, and how evidence-based approaches can transform lives and healthcare delivery. Our focus on outcome-based care ensures that every intervention we support leads to measurable improvements in well-being and recovery.
Expert clinicians dedicated to TRS ACCESS services
Professor of Clinical Psychiatry, Harvard Medical School
Co-director, MGH Psychosis Clinical and Research Program
Oliver Freudenreich directs the TRS ACCESS program and leads our consultation service, providing expert guidance to clinicians managing complex cases and supporting clinicians to become capable of prescribing clozapine safely and effectively.
View publications
Assistant Professor of Psychiatry, Harvard Medical School
Director of Clinical Services, MGH Psychosis Clinical and Research Program
Abigail Donovan specializes in the early detection and treatment of schizophrenia in adolescents and adults, with a focus on outcome-based care and quality improvement initiatives.
View publications
Assistant Professor of Psychiatry, Harvard Medical School
Medical Director, MGH Clozapine Clinic
Carol Lim serves as the medical director of our Clozapine Clinic and leads educational initiatives to help other healthcare systems establish safe and effective clozapine monitoring programs.
View publications
Psychiatric Nurse Practitioner & LAI Specialist
Sarah Maclaurin provides expert clinical care and specializes in long-acting injectable antipsychotic medications, offering consultation and training to healthcare providers.
Assistant Professor of Psychology, Harvard Medical School
Clinical Psychologist & Implementation Specialist
Cheryl Foo leads implementation efforts to help clinicians and healthcare systems become capable of prescribing clozapine and long-acting injectables safely and effectively.
View publications
Program Coordinator
Marta Hernandez coordinates program activities and provides administrative support to ensure seamless patient care and program operations.
Program Manager
Leah Namey manages program operations and oversees quality improvement initiatives within the TRS ACCESS program.
Comprehensive support for evidence-based TRS care
Direct clinical services and case consultation
Expert consultation for clinicians managing complex cases of difficult to treat psychosis, providing guidance on diagnosis, treatment planning, and clozapine initiation and management.
Oliver Freudenreich, MD on consultation services
The TRS ACCESS Network is part of the MGH Psychosis Clinical and Research Program (PCRP), which provides comprehensive clinical care for patients with psychotic disorders.
Go to the MGH PCRP websiteHelping clinics and health systems build the capacity to deliver safe, effective TRS care
We specialize in optimizing clozapine treatment, navigating today's regulatory landscape to ensure safe, effective prescribing. Our support includes protocol development, staff training, and education to uphold best practices in clozapine management.
Carol Lim, MD on clozapine clinic services
Training and consultation on long-acting injectable antipsychotic medications, helping clinicians optimize medication adherence and improve treatment outcomes.
Sarah Maclaurin, PMHNP-BC on LAI expertise
Implementation support to help healthcare systems and clinicians become capable of prescribing clozapine and long-acting injectable safely and effectively, including staff training, workflow development, and ongoing support.
Cheryl Foo, PhD on program implementation
Invite our faculty to speak with your team
Our faculty are available to deliver Grand Rounds, lectures, case conferences, and educational presentations on schizophrenia, clozapine, long-acting injectables, and related topics. We welcome invitations from academic medical centers, hospitals, community clinics, residency and fellowship programs, and professional organizations.
Please contact us with the proposed date, audience, format, and topic you have in mind.
Educational materials and publications from our faculty
Evidence-based clinical guidance from the MGH Psychosis Clinical and Research Program.
View / Download PDFArgues that the end of the clozapine REMS program is an opportunity to redesign monitoring so that medical follow-up tracks a clinical treatment framework with three phases: clozapine trial, treatment optimization, and treatment consolidation.
View ArticleA mixed-methods study of real-world adoption of a point-of-care fingerstick device for neutrophil monitoring at two outpatient clinics, finding that successful implementation depends on addressing patient preferences, staffing logistics, and sustainable financing.
View ArticleA conceptual review arguing for early and routine use of clozapine in treatment-resistant schizophrenia within a stage-based treatment framework, reviewing its broad-spectrum advantages and outlining strategies for safe use and for overcoming barriers to utilization.
View Article
Second Edition - A comprehensive guide to understanding and treating psychotic disorders in clinical practice.
A guide for patients and families dealing with serious mental illness.
Emergency Management - A comprehensive guide for managing substance use in psychiatric emergencies.
And Other Stories from the World of Emergency Psychiatry.
Oliver Freudenreich, MD discusses secondary psychosis and differential diagnosis considerations.
Abigail Donovan, MD explains the spectrum of schizophrenia, covering causes, symptoms, and treatment approaches.
Educational presentation on treatment-resistant schizophrenia and clozapine therapy approaches.
Research seminar discussing current clinical research initiatives in psychosis treatment and management.
Get in touch with our specialized team
151 Merrimac St, Suite 401
Boston, MA 02114
617-643-1175